CHP Merger stockholders voted in favor of extending the SPAC’s merger deadline with Accelus from Nov. 26 until May 26.
Accelus is a medical technology company focused on the spinal surgery market.
The deal values the combined compny at $482 million. If the transaction is approved, funding will come from $300 million held in the SPAC’s trust, as well as $414 million in Acdelus rollover equity, according to a slide deck filed (p. 34) in an 8-K. Read more.
